Biopsy
The pap smear can be used as a screening
test, but is false
negative in up
to 50% of cases of cervical cancer. Confirmation
of the diagnosis of cervical cancer or pre-cancer requires a biopsy of the
cervix. This is often done through colposcopy, a
magnified visual inspection of the cervix aided by using a dilute acetic acid (e.g.vinegar)
solution to highlight abnormal cells on the surface of the cervix. Medical devices used for biopsy of the
cervix include punch forceps, SpiraBrush
CX,SoftBiopsy or Soft-ECC.
Colposcopic impression, the
estimate of disease severity based on the visual inspection, forms part of the
diagnosis.
Further diagnostic and
treatment procedures are loop electrical excision
procedure(LEEP) and conization, in
which the inner lining of the cervix is removed to be examined pathologically.
These are carried out if the biopsy confirms severe cervical intraepithelial
neoplasia.
This
large squamous carcinoma (bottom of picture) has obliterated the cervix and
invaded the lower uterine segment. The uterus also has a roundleiomyoma up higher.
Often before the biopsy, the
doctor asks for medical imaging to rule out other causes of woman's symptoms.
Imaging modalities including ultrasound, CT
scan and MRI have been used to different extent in order to look for
alternating disease/spread of tumor/effect on adjacent structures. Typically
they appear as heterogeneous mass in the cervix.
Precancerous lession
Cervical intraepithelial
neoplasia, the potential precursor to cervical cancer, is often diagnosed
on examination of cervical biopsies by a pathologist. For
premalignant dysplastic changes, the CIN (cervical intraepithelial
neoplasia) grading is used.
The naming and histologic classification of cervical carcinoma
precursor lesions has changed many times over the 20th century. The World Health Organizationclassification system was descriptive of the lesions,
naming them mild, moderate or severe dysplasia or carcinoma
in situ (CIS).
The term, Cervical Intraepithelial
Neoplasia (CIN)
was developed to place emphasis on the spectrum of abnormality in these
lesions, and to help standardise treatment. It
classifies mild dysplasia as CIN1, moderate dysplasia as CIN2, and severe
dysplasia and CIS as CIN3. More recently, CIN2 and CIN3 have been combined into
CIN2/3. These results are what a pathologist might report from a biopsy.
These should not be confused
with the Bethesda
System terms
for Pap smear (cytopathology) results. Among the Bethesda
results: Low-grade Squamous
Intraepithelial Lesion (LSIL) and High-grade Squamous
Intraepithelial Lesion (HSIL). An LSIL Pap may correspond to
CIN1, and HSIL may correspond to CIN2 and CIN3, however they are results of different
tests, and the Pap smear results need not match the histologic findings.
Cancer subtypes
Histologic subtypes of invasive cervical carcinoma
include the following:Though squamous cell carcinoma is the cervical cancer
with the most incidence, the incidence of adenocarcinoma of the cervix has been
increasing in recent decades.
·
squamous cell carcinoma (about 80-85%)
·
adenocarcinoma (about 15% of cervical cancers in the UK)
Non-carcinoma malignancies
which can rarely occur in the cervix include
·
melanoma
·
lymphoma
Note that the FIGO stage does
not incorporate lymph
node involvement
in contrast to the TNM staging
for most other cancers.
For cases treated surgically,
information obtained from the pathologist can be used in assigning a separate
pathologic stage but is not to replace the original clinical stage.
Staging
Cervical
cancer is staged by the International Federation of Gynecology and Obstetrics (FIGO) staging system,
which is based on clinical examination, rather than surgical findings. It
allows only the following diagnostic tests to be used in determining the stage:
palpation, inspection, colposcopy,
endocervical curettage, hysteroscopy, cystoscopy, proctoscopy, intravenous urography, and X-ray examination of the lungs
and skeleton, and cervical conization.

No comments:
Post a Comment